270 related articles for article (PubMed ID: 18090391)
1. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.
Smith CJ; Olsen CH; Mocroft A; Viard JP; Staszewski S; Panos G; Staub T; Blaxhult A; Vetter N; Lundgren JD
AIDS; 2008 Jan; 22(1):47-56. PubMed ID: 18090391
[TBL] [Abstract][Full Text] [Related]
2. The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients.
Dragovic G; Jevtovic D
Biomed Pharmacother; 2012 Jun; 66(4):308-11. PubMed ID: 22658063
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
4. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
5. Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort.
Fessel J; Hurley LB
AIDS; 2008 Jan; 22(1):145-7. PubMed ID: 18090403
[No Abstract] [Full Text] [Related]
6. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Moore RD; Keruly JC; Chaisson RE
AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
[TBL] [Abstract][Full Text] [Related]
7. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
[TBL] [Abstract][Full Text] [Related]
8. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.
Cotte L; Bénet T; Billioud C; Miailhes P; Scoazec JY; Ferry T; Brochier C; Boibieux A; Vanhems P; Chevallier M; Zoulim F
J Hepatol; 2011 Mar; 54(3):489-96. PubMed ID: 21056493
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.
Bonnet F; Bonarek M; Morlat P; Mercié P; Dupon M; Gemain MC; Malvy D; Bernard N; Pellegrin JL; Beylot J
Clin Infect Dis; 2003 May; 36(10):1324-8. PubMed ID: 12746780
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
12. Class of antiretroviral drugs and the risk of myocardial infarction.
; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD
N Engl J Med; 2007 Apr; 356(17):1723-35. PubMed ID: 17460226
[TBL] [Abstract][Full Text] [Related]
13. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.
Walker UA; Bäuerle J; Laguno M; Murillas J; Mauss S; Schmutz G; Setzer B; Miquel R; Gatell JM; Mallolas J
Hepatology; 2004 Feb; 39(2):311-7. PubMed ID: 14767983
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.
Blanco F; Barreiro P; Ryan P; Vispo E; Martín-Carbonero L; Tuma P; Labarga P; Medrano J; González-Lahoz J; Soriano V
J Viral Hepat; 2011 Jan; 18(1):11-6. PubMed ID: 20088890
[TBL] [Abstract][Full Text] [Related]
15. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.
Boubaker K; Flepp M; Sudre P; Furrer H; Haensel A; Hirschel B; Boggian K; Chave JP; Bernasconi E; Egger M; Opravil M; Rickenbach M; Francioli P; Telenti A
Clin Infect Dis; 2001 Dec; 33(11):1931-7. PubMed ID: 11692306
[TBL] [Abstract][Full Text] [Related]
16. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
17. Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.
Hwang SW; Leo YS
Singapore Med J; 2001 Jun; 42(6):247-51. PubMed ID: 11547960
[TBL] [Abstract][Full Text] [Related]
18. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.
Capeau J; Bouteloup V; Katlama C; Bastard JP; Guiyedi V; Salmon-Ceron D; Protopopescu C; Leport C; Raffi F; Chêne G;
AIDS; 2012 Jan; 26(3):303-14. PubMed ID: 22089377
[TBL] [Abstract][Full Text] [Related]
19. New questions about an old combination--ddI + d4T.
Proj Inf Perspect; 2003 Jan; (35):13-4. PubMed ID: 12647675
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, incidence and predictors of peripheral neuropathy in African adults with HIV infection within the DART trial.
Kiwuwa-Muyingo S; Kikaire B; Mambule I; Musana H; Musoro G; Gilks CF; Levin JB; Walker AS
AIDS; 2014 Nov; 28(17):2579-88. PubMed ID: 25574960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
